Helping Patients Afford Estradiol/Norethindrone/Relugolix

You've diagnosed the fibroids or endometriosis. You've determined that Myfembree (Estradiol/Norethindrone/Relugolix) is the right treatment. The patient agrees to start — and then they see the price.

At $1,300 to $1,700 per month without insurance, Estradiol/Norethindrone/Relugolix is one of the most expensive oral medications your patients may encounter. Even with insurance, specialty tier copays, prior authorization requirements, and step therapy barriers can create real financial obstacles. When patients can't afford their medication, they don't take it — and the clinical outcomes you're working toward don't materialize.

This guide is a practical resource for providers and their staff to help patients navigate the cost landscape for Myfembree, from manufacturer programs to patient assistance options.

What Patients Are Actually Paying

Understanding the financial reality helps you have better conversations with patients:

• Cash price (uninsured): $1,300–$1,700 for a 28-tablet (1-month) supply
• Commercial insurance with prior authorization: Copays vary widely — anywhere from $30 to $300+ per month depending on formulary tier and plan design. Most plans classify Myfembree as a specialty tier drug.
• Medicare/Medicaid: Coverage varies significantly by plan. Some Medicare Part D plans cover it with prior authorization; Medicaid coverage depends on state formularies.
• With manufacturer copay assistance (commercial insurance): As low as $5 per fill

The takeaway: the sticker price rarely reflects what patients actually pay, but without proactive guidance from your office, many patients assume the worst and never fill the prescription.

Manufacturer Savings Programs

Myfembree Copay Assistance Program

This is the first program to recommend for commercially insured patients:

• Eligible patients: Those with commercial (private) insurance
• Savings: As little as $5 per fill for a 28-day supply, or $15 for a 90-day supply
• Annual maximum: $5,000 in savings per year
• Not eligible: Patients on Medicare, Medicaid, TRICARE, or other government-funded insurance programs
• How to enroll: Through myfembree.com/cost-and-support or via the TrialCard portal. Your office staff can help patients enroll during the appointment or provide enrollment materials at checkout.

Practical tip for your team: Keep printed copay assistance enrollment forms at the front desk or in the checkout area. Train your medical assistants to mention the program when rooming patients who are starting or continuing Myfembree. The 30 seconds it takes to mention the program can be the difference between a patient filling or abandoning their prescription.

Myovant Sciences Patient Assistance Program

For patients who are uninsured or underinsured and experiencing financial hardship:

• Eligible patients: Uninsured or underinsured patients who meet income criteria
• What it provides: Free or reduced-cost medication
• How to apply: Contact Myovant patient services directly or apply through third-party organizations

This is less commonly used than the copay program but can be a lifeline for patients without adequate coverage.

Coupon and Discount Card Programs

For patients paying cash or facing high copays that exceed the manufacturer program's benefit, third-party discount programs may help:

• GoodRx — Shows pharmacy-specific pricing for Myfembree. Prices through GoodRx are typically still high for brand-name specialty drugs, but it's worth checking.
• SingleCare — Another discount card option that can sometimes offer competitive pricing at specific pharmacies.
• RxSaver, Optum Perks, BuzzRx — Additional coupon card platforms that aggregate pharmacy pricing.

A realistic note: for a brand-name specialty medication like Myfembree with no generic available, coupon cards typically provide modest savings compared to the manufacturer's copay assistance program. They're most useful for patients who don't qualify for the manufacturer program (e.g., those on government insurance) or who are paying entirely out of pocket.

For a comprehensive patient-facing guide, refer patients to our article on how to save money on Estradiol/Norethindrone/Relugolix.

Generic Alternatives and Therapeutic Substitution

Generic Status

As of March 2026, no generic version of Myfembree is available. Patent exclusivities began expiring in late 2025/early 2026, and generic entry may occur in 2026, but nothing has been approved yet. When a generic does become available, it will likely offer significant cost savings — potentially reducing the monthly cost to a fraction of the brand price.

Therapeutic Alternatives

If cost is an insurmountable barrier, consider whether a therapeutic alternative might be appropriate for your patient:

• Oriahnn (Elagolix/Estradiol/Norethindrone Acetate) — Another GnRH antagonist combination with add-back therapy, approved for fibroid-related heavy bleeding. Requires twice-daily dosing with different morning and evening capsules. Check whether the patient's insurance covers Oriahnn more favorably.
• Orilissa (Elagolix) — A GnRH antagonist without built-in add-back therapy, approved for endometriosis. Available in 150 mg (once daily) and 200 mg (twice daily) doses. You can prescribe separate add-back therapy alongside it. May be covered differently by insurance.
• Lupron Depot (Leuprolide Acetate) — An injectable GnRH agonist. While it has more significant side effects (hormonal flare, greater bone loss without add-back), some insurance plans cover it more readily, and the injection route means guaranteed adherence. Consider this for patients who need short-term preoperative fibroid management.
• Hormonal IUDs (Mirena) — For fibroid-related heavy bleeding specifically, a levonorgestrel IUD may be a cost-effective first-line option. It doesn't shrink fibroids but can significantly reduce bleeding for up to 8 years. Many plans cover IUDs with minimal cost-sharing.

For a full comparison of alternatives, see our clinical guide on alternatives to Estradiol/Norethindrone/Relugolix.

Insurance Navigation Tips

• Prior authorization: Most plans require PA for Myfembree. Submit documentation early — include imaging results, symptom severity scores, and documentation of failed or contraindicated first-line therapies to strengthen the case.
• Step therapy appeals: If the plan requires step therapy (e.g., trying a hormonal IUD first), document medical reasons why the required step is inappropriate for your patient. Common reasons include contraindications, prior failures, or anatomical factors.
• Peer-to-peer review: If PA is denied, request a peer-to-peer review promptly. Having clinical documentation ready can make these conversations more productive.

Building Cost Conversations into Your Workflow

Many providers feel uncomfortable discussing medication costs, but it's one of the most impactful things you can do for adherence. Here's how to make it routine:

At the Point of Prescribing

• Name the cost upfront: "Myfembree is an effective option, but it's expensive — about $1,500 a month without help. The good news is there are programs that can bring your cost down to as little as $5. Let me have my team help you get set up."
• Normalize the conversation: Patients are often embarrassed to bring up cost. When you bring it up first, you give them permission to be honest about their financial situation.

Staff Training

• Train front desk and medical assistant staff to provide copay assistance enrollment forms to every patient starting Myfembree
• Designate a staff member (or use your existing prior authorization coordinator) to handle manufacturer program enrollments
• Create a one-page handout with savings resources that patients can take home

Follow-Up

• At the first follow-up visit, ask: "Were you able to fill the prescription? Any issues with cost?"
• If a patient reports they didn't fill it, explore whether cost, pharmacy access, or side effect concerns were the barrier
• If patients are struggling to find the medication in stock, direct them to Medfinder for Providers — a tool that helps locate pharmacies with specialty medications available

Additional Resources

• NeedyMeds (needymeds.org) — Comprehensive database of patient assistance programs
• RxAssist (rxassist.org) — Another directory of pharmaceutical company assistance programs
• RxHope (rxhope.com) — Helps patients apply for patient assistance programs

Final Thoughts

Cost should never be the reason a patient with debilitating fibroid bleeding or endometriosis pain goes untreated. With Myfembree's manufacturer copay program bringing costs as low as $5 for commercially insured patients, and patient assistance programs available for the uninsured, there are real options — but patients often need their provider's office to help them navigate the system.

Building cost conversations and savings program enrollment into your prescribing workflow takes minimal effort and can dramatically improve fill rates and treatment adherence. Your patients will thank you — and their outcomes will reflect it.

Learn more about Medfinder for Providers →